An observational study on the cardiovascular benefits and safety of sacubitril-valsartan in the treatment of stage 5 chronic kidney disease complicated with refractory hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058161

Enrollment

Unknown

Registered

2022-03-31

Start date

2022-04-30

Completion date

Unknown

Last updated

2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, male or female; 2. Meet the diagnostic criteria for stage 5 chronic kidney disease: evidence of kidney injury for more than 3 months, eGFR =3 kinds of antihypertensive drugs (including diuretics, calcium channel blockers, B receptor blockers and a receptor blockers) should be rationally used for treatment, but blood pressure control is still not up to standard (>= 140/90 mmHg, >= 130/80 mmHg for patients with diabetes or kidney disease).?Or the use of four types of blood pressure medications to control high blood pressure.

Exclusion criteria

Exclusion criteria: 1. Symptomatic hypotension (systolic BP 5.5mmol/L; 5. Those who have previously received ACEI or ARB intolerance; 6. Cirrhosis or severe liver damage (Child-Pugh grade C); 7. Patients with other serious systemic diseases, such as malignant tumors; 8. Missing important information.

Design outcomes

Secondary

Measure	Time frame
Brain Natriuretic Peptide, BNP;Left ventricular ejection fraction;Left Ventricular end-diastolic diameter;	—

Primary

Measure	Time frame
Blood pressure;NYHA grading of cardiac function;	—

Countries

China

Contacts

Public ContactLiao Yunhua

The First Affiliated Hospital of Guangxi Medical University

993237105@qq.com+86 13878889238

Outcome results